References

Antiinflammatory therapy with canakinumab for atherosclerotic disease

10.1056/nejmoa1707914 · 2017 · External reference

Efficacy and safety of low-dose colchicine after myocardial infarction

10.1056/nejmoa1912388 · 2019 · External reference

Low-dose colchicine for secondary prevention of cardiovascular disease

10.1016/j.jacc.2012.10.027 · 2013 · External reference

Colchicine in patients with chronic coronary disease

10.1056/nejmoa2021372 · 2020 · External reference

Macrophage in chronic kidney disease

10.1093/ckj/sfw096 · 2016 · External reference

Macrophage functional diversity in NAFLD - more than inflammation

10.1038/s41574-022-00675-6 · 2022 · External reference

Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy

10.1093/eurheartj/ehag117 · 2026 · External reference

Abandoning M1/M2 for a network model of macrophage function

10.1161/circresaha.116.309194 · 2016 · External reference

Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics

10.1161/circresaha.120.316770 · 2020 · External reference

Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis

10.1093/cvr/cvac161 · 2023 · External reference

Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches

10.1016/j.cell.2021.12.018 · 2022 · External reference

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

10.1038/s41586-019-1631-3 · 2019 · External reference

Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner

10.1016/j.cell.2019.05.054 · 2019 · External reference

Infiltrative classical monocyte-derived and SPP1 lipid-associated macrophages mediate inflammation and fibrosis in ANCA-associated glomerulonephritis

10.1093/ndt/gfae292 · 2025 · External reference

Lipid-associated macrophages between aggravation and alleviation of metabolic diseases

10.1016/j.tem.2024.04.009 · 2024 · External reference

Monocyte and macrophage lipid accumulation results in down-regulated type-I interferon responses

10.3389/fcvm.2022.829877 · 2022 · External reference

Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice

2007 · External reference

Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses

10.1016/j.cell.2012.06.054 · 2012 · External reference

X-ray structures of the LXRα LBD in its homodimeric form and implications for heterodimer signaling

10.1016/j.jmb.2010.04.005 · 2010 · External reference

LXR, a nuclear receptor that defines a distinct retinoid response pathway

10.1101/gad.9.9.1033 · 1995 · External reference

Genome-wide landscape of liver X receptor chromatin binding and gene regulation in human macrophages

10.1186/1471-2164-13-50 · 2012 · External reference

Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities

10.1016/j.molcel.2010.05.004 · 2010 · External reference

Liver X receptors interact with corepressors to regulate gene expression

10.1210/me.2002-0399 · 2003 · External reference

Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression

10.1128/mcb.23.16.5780-5789.2003 · 2003 · External reference

Insights into the function of HDAC3 and NCoR1/NCoR2 co-repressor complex in metabolic diseases

10.3389/fmolb.2023.1190094 · 2023 · External reference

Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis

10.1016/j.ccell.2015.05.007 · 2015 · External reference

Research resource: comparative nuclear receptor atlas: basal and activated peritoneal B-1 and B-2 cells

10.1210/me.2010-0384 · 2011 · External reference

Common and differential transcriptional actions of nuclear receptors liver X receptors α and β in macrophages

10.1128/mcb.00376-18 · 2019 · External reference

Structural characterisation of the mouse nuclear oxysterol receptor genes LXRα and LXRβ

10.1016/s0378-1119(99)00555-7 · 2000 · External reference

Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands

10.1074/jbc.m603781200 · 2006 · External reference

Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ

10.1073/pnas.96.1.266 · 1999 · External reference

The challenges and promise of targeting the liver X receptors for treatment of inflammatory disease

10.1016/j.pharmthera.2017.07.010 · 2018 · External reference

Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease

10.1016/j.bbrc.2016.09.036 · 2016 · External reference

Inhibition of LXR signaling in human foam cells impairs macrophage-to-endothelial cell cross talk and promotes endothelial cell inflammation

10.1161/atvbaha.125.322448 · 2025 · External reference

Inhibition of LXR controls the polarization of human inflammatory macrophages through upregulation of MAFB

10.1007/s00018-023-04745-4 · 2023 · External reference

Current understanding on the role of lipids in macrophages and associated diseases

10.3390/ijms24010589 · 2022 · External reference

Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels

10.1161/atvbaha.107.156935 · 2008 · External reference

Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice

10.1161/circresaha.113.301086 · 2013 · External reference

Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo

10.1172/jci32057 · 2007 · External reference

Transcriptional regulation of macrophage cholesterol efflux and atherogenesis by a long noncoding RNA

10.1038/nm.4479 · 2018 · External reference

Liver X receptors in lipid signalling and membrane homeostasis

10.1038/s41574-018-0037-x · 2018 · External reference

SREBP1 contributes to resolution of pro-inflammatory TLR4 signaling by reprogramming fatty acid metabolism

10.1016/j.cmet.2016.11.009 · 2017 · External reference

Liver X receptor activation promotes polyunsaturated fatty acid synthesis in macrophages: relevance in the context of atherosclerosis

10.1161/atvbaha.115.305539 · 2015 · External reference

Regulated necrosis in atherosclerosis

10.1161/atvbaha.122.318177 · 2022 · External reference

Foam cells in atherosclerosis: novel insights into its origins, consequences, and molecular mechanisms

10.3389/fcvm.2022.845942 · 2022 · External reference

Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols

10.1016/0002-9149(80)90516-0 · 1980 · External reference

HDL and reverse cholesterol transport

10.1161/circresaha.119.312617 · 2019 · External reference

Myeloid LXR (liver X receptor) deficiency induces inflammatory gene expression in foamy macrophages and accelerates atherosclerosis

10.1161/atvbaha.122.317583 · 2022 · External reference

Activation of liver X receptor decreases atherosclerosis in ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells

10.1161/atvbaha.113.302781 · 2014 · External reference

Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis

10.1073/pnas.2107682118 · 2021 · External reference

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms

10.1194/jlr.m800374-jlr200 · 2009 · External reference

DHCR24 inhibitor SH42 increases desmosterol without preventing atherosclerosis development in mice

10.1016/j.isci.2024.109830 · 2024 · External reference

Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils

10.1016/j.cmet.2016.07.016 · 2016 · External reference

Synthetic high-density lipoprotein-mediated targeted delivery of liver X receptors agonist promotes atherosclerosis regression

10.1016/j.ebiom.2017.12.021 · 2018 · External reference

Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development

10.1016/j.bcp.2013.09.019 · 2013 · External reference

Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis

10.1002/cti2.1446 · 2023 · External reference

Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles

10.1074/jbc.m204887200 · 2002 · External reference

Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation

10.15252/emmm.202216845 · 2023 · External reference

Lipid droplet accumulation is associated with an increase in hyperglycemia-induced renal damage: prevention by liver X receptors

10.1016/j.ajpath.2012.11.033 · 2013 · External reference

Improvement of LXR-mediated lipid metabolism in nephrotic model kidney accompanied by suppression of inflammation and fibrosis

10.1016/j.bbrc.2023.05.019 · 2023 · External reference

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

10.1038/s41591-025-04169-6 · 2026 · External reference

A liver-selective LXR inverse agonist that suppresses hepatic steatosis

10.1021/cb300541g · 2013 · External reference

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

10.1016/j.molmet.2015.01.009 · 2015 · External reference

Liver X receptor inverse agonist SR9243 suppresses nonalcoholic steatohepatitis intrahepatic inflammation and fibrosis

10.1155/2018/8071093 · 2018 · External reference

Inhibition of hepatotoxicity by a LXR inverse agonist in a model of alcoholic liver disease

10.1021/acsptsci.8b00003 · 2018 · External reference

A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis

10.1371/journal.pone.0249316 · 2021 · External reference

Antihyperlipidemic activity of gut-restricted LXR inverse agonists

10.1021/acschembio.2c00057 · 2022 · External reference

Sophoricoside is a selective LXRβ antagonist with potent therapeutic effects on hepatic steatosis of mice

10.1002/ptr.6747 · 2020 · External reference

Macrophages in atherosclerosis regression

10.1161/atvbaha.119.312802 · 2020 · External reference

Liver-derived signals sequentially reprogram myeloid enhancers to initiate and maintain Kupffer cell identity

10.1016/j.immuni.2019.09.002 · 2019 · External reference

Liver X receptors and liver physiology

10.1016/j.bbadis.2021.166121 · 2021 · External reference

Liver X receptors as integrators of metabolic and inflammatory signaling

10.1172/jci27883 · 2006 · External reference

Role of LXRs in control of lipogenesis

10.1101/gad.850400 · 2000 · External reference

Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages

10.1073/pnas.1714518115 · 2018 · External reference

Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution

10.1073/pnas.1911992116 · 2019 · External reference

New chemotype of selective and potent inhibitors of human delta 24-dehydrocholesterol reductase

10.1016/j.ejmech.2017.08.011 · 2017 · External reference

Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants

10.1177/0091270009335768 · 2009 · External reference

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases

10.3389/fmed.2023.1102469 · 2023 · External reference

Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health

10.1038/s42255-024-01126-4 · 2024 · External reference

Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease

10.1038/s41581-023-00741-w · 2023 · External reference

An overview of chronic kidney disease pathophysiology: the impact of gut dysbiosis and oral disease

10.3390/biomedicines11113033 · 2023 · External reference

Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism

10.1186/s12882-018-0814-8 · 2018 · External reference

Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ

10.1016/j.molcel.2006.11.022 · 2007 · External reference

Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways

10.1101/gad.1773109 · 2009 · External reference

LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling

10.7554/elife.08009 · 2015 · External reference

LXR suppresses inflammatory gene expression and neutrophil migration through cis-repression and cholesterol efflux

10.1016/j.celrep.2018.11.100 · 2018 · External reference

Reprogramming of the LXRα transcriptome sustains macrophage secondary inflammatory responses

10.1002/advs.202307201 · 2024 · External reference

Liver X receptor-dependent inhibition of microglial nitric oxide synthase 2

10.1186/s12974-015-0247-2 · 2015 · External reference

Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1β secretion

10.1093/cvr/cvac189 · 2023 · External reference

Cholesterol efflux pathways suppress inflammasome activation, NETosis, and atherogenesis

10.1161/circulationaha.117.032636 · 2018 · External reference

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

10.1126/scitranslmed.aad6100 · 2016 · External reference

Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense

10.4049/jimmunol.180.5.3305 · 2008 · External reference

The nuclear receptor LXR limits bacterial infection of host macrophages through a mechanism that impacts cellular NAD metabolism

10.1016/j.celrep.2017.01.007 · 2017 · External reference

LXR-Dependent Gene expression is important for macrophage survival and the innate immune response

10.1016/j.cell.2004.09.032 · 2004 · External reference

Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice

10.1172/jci35288 · 2009 · External reference

Liver X receptor protects against liver injury in sepsis caused by rodent cecal ligation and puncture

10.1089/sur.2010.066 · 2011 · External reference

Liver X receptor beta deficiency attenuates autoimmune-associated neuroinflammation in a T cell-dependent manner

10.1016/j.jaut.2021.102723 · 2021 · External reference

Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages

10.1161/circresaha.106.135814 · 2007 · External reference

LXR activation induces a proinflammatory trained innate immunity-phenotype in human monocytes

10.3389/fimmu.2020.00353 · 2020 · External reference

LXRα regulates oxLDL-induced trained immunity in macrophages

10.3390/ijms23116166 · 2022 · External reference

Activation of LXR nuclear receptors impairs the anti-inflammatory gene and functional profile of M-CSF-dependent human monocyte-derived macrophages

10.3389/fimmu.2022.835478 · 2022 · External reference

Defining GM-CSF– and macrophage-CSF–dependent macrophage responses by in vitro models

10.4049/jimmunol.1103426 · 2012 · External reference

Active LXR signaling, coupled with elevated mitochondrial and glycolytic metabolism contributes to GM-CSF–induced trained immunity

10.3389/fimmu.2025.1685796 · 2026 · External reference

Interplay between liver X receptor and hypoxia inducible factor 1α potentiates interleukin-1β production in human macrophages

10.1016/j.celrep.2020.107665 · 2020 · External reference

Autoregulation of the human liver X receptor α promoter

10.1128/mcb.21.22.7558-7568.2001 · 2001 · External reference

Genome-wide analysis of LXRα activation reveals new transcriptional networks in human atherosclerotic foam cells

10.1093/nar/gkt034 · 2013 · External reference

Efferocytosis potentiates the expression of arachidonate 15-lipoxygenase (ALOX15) in alternatively activated human macrophages through LXR activation

10.1038/s41418-020-00652-4 · 2021 · External reference

Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis

10.1038/s44161-023-00354-3 · 2023 · External reference

TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge

10.1016/j.neuron.2019.12.007 · 2020 · External reference

TREM2 in cardiovascular diseases: mechanisms and therapeutic perspectives

10.1016/j.arr.2025.102774 · 2025 · External reference

Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis, increasing the risk of cerebrovascular complications

10.1038/s44161-023-00295-x · 2023 · External reference

Complement receptor targeted liposomes encapsulating the liver X receptor agonist GW3965 accumulate in and stabilize atherosclerotic plaques

10.1002/adhm.202000043 · 2020 · External reference

Targeted delivery of liver X receptor agonist to inhibit neointimal hyperplasia by differentially regulating cell behaviors

10.1039/d2bm01041k · 2022 · External reference